It has an oral bioavailability of 80%, protein binding of >99%, metabolism sites of the GI mucosa and liver, volume of distribution (Vd) of 0.13 L/kg, elimination half-life of 14–18 days and excretion routes of faeces (48%) and urine (43%).
Leflunomide
Tofacitinib
Etanercept
Teriflunomide
Belatacept
Belimumab
Adalimumab
Anakinra